Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
OPERATING ACTIVITIES:
Consolidated net loss	$ (581)	$ 226
Adjustments to reconcile consolidated net income to net cash provided by (used in) operating activities:
Bad debt expense	80	6
Depreciation and amortization	1,165	618
Stock-based compensation expense	441	307
Amortization of debt issuance cost	4	1
Tax payments related to shares cancelled for vested restricted stock awards	(10)	(16)
Deferred income taxes	(706)	64
Changes in operating assets and liabilities:
Trade accounts receivable	240	1,692
Inventories	668	(3,987)
Other current assets	4,026	(1,026)
Right of use assets	346	(25)
Other long-term assets	(0)	363
Accounts payable	454	(1,579)
Accrued expenses	(3,441)	2,443
Income taxes payable	(462)	0
Net cash provided by operating activities	2,224	(1,639)
INVESTING ACTIVITIES:
Capital expenditures	(1,303)	(268)
Purchase of Microlab, net of cash acquired ($33)	0	(24,217)
Net cash used in investing activities	(1,303)	(24,485)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	85	57
Debt issuance cost	0	(32)
Term Loan payments	(1,212)	(202)
Term Loan	0	17,000
Net cash used in financing activities	(1,127)	16,823
Net (decrease) increase in cash and cash equivalents	(206)	(9,301)
Cash and cash equivalents, beginning of period	4,532	13,053
Cash and cash equivalents, end of period	4,326	3,752
Supplemental cash flow information – income taxes paid	$ 0	$ 340